129 related articles for article (PubMed ID: 21046268)
1. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Takamori H; Kanemitsu K; Hirota M; Ikeda O; Tanaka H; Beppu T; Yamashita Y; Oya N; Baba H
Ann Surg Oncol; 2011 Apr; 18(4):1110-5. PubMed ID: 21046268
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Habermehl D; Brecht IC; Bergmann F; Welzel T; Rieken S; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2013 Jan; 8():27. PubMed ID: 23369246
[TBL] [Abstract][Full Text] [Related]
7. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Kurosaki I; Kawachi Y; Nihei K; Tsuchiya Y; Aono T; Yokoyama N; Shimizu T; Hatakeyama K
Pancreas; 2009 Mar; 38(2):161-7. PubMed ID: 18797423
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
9. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion chemotherapy reduced hepatic metastases from pancreatic cancer after pancreatectomy.
Zheng YY; Tang CW; Xu YQ; Feng WM; Bao Y; Fei MY
Hepatogastroenterology; 2014; 61(133):1415-20. PubMed ID: 25436319
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
12. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Miyanishi K; Ishiwatari H; Hayashi T; Takahashi M; Kawano Y; Takada K; Ihara H; Okuda T; Takanashi K; Takahashi S; Sato Y; Matsunaga T; Homma H; Kato J; Niitsu Y
Jpn J Clin Oncol; 2008 Apr; 38(4):268-74. PubMed ID: 18375446
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Cardenes HR; Moore AM; Johnson CS; Yu M; Helft P; Chiorean EG; Vinson J; Howard TJ; Stephens AW; Tai DF; Loehrer PJ
Am J Clin Oncol; 2011 Oct; 34(5):460-5. PubMed ID: 20881474
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
